Skip to main content

Search

Reset all filters
839 Result(s)
Sort by

Micardis®

Micardis®

Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
Facts About Asthma

Facts About Asthma

Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
Results for Jardiance EMPACT-MI phase III trial

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
2019 performance

2019 performance

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
FDA-CRL-T1D

FDA-CRL-T1D

US FDA issues complete response letter for treatment of adults with type 1 diabetes
Phase II trials for patients with bronchiectasis

Phase II trials for patients with bronchiectasis

Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Julia Sonnermann

Julia Sonnermann

Julia Sonnermann on transforming lives for generations
Taimi Sahlin

Taimi Sahlin

Independent, authentic, bold - Taimi Sahlin’s career path
Aiko Watabe

Aiko Watabe

Prioritizing development with Aiko Watabe
Nelli Milosch

Nelli Milosch

Nelli Milosch on what makes our people different
clinical_collaboration_with_Mirati

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.